We are live on ! Find out more
IBB icon

iShares Biotechnology ETF
IBB

624 hedge funds and large institutions have $5.69B invested in iShares Biotechnology ETF in 2017 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 207 increasing their positions, 192 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more first-time investments, than exits

New positions opened: 124 | Existing positions closed: 77

7% more funds holding

Funds holding: 583 → 624 (+41)

8% more repeat investments, than reductions

Existing positions increased: 207 | Existing positions reduced: 192

0% more funds holding in top 10

Funds holding in top 10: 30 → 30 (0)

12% less capital invested

Capital invested by funds: $6.44B → $5.69B (-$749M)

57% less call options, than puts

Call options by funds: $533M | Put options by funds: $1.25B

127.95% less ownership

Funds ownership: 186.53% → 58.57% (-128%)

Holders
624
Holders Change
+41
Holders Change %
+7.03%
% of All Funds
14.15%
Holding in Top 10
30
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.68%
New
124
Increased
207
Reduced
192
Closed
77
Calls
$533M
Puts
$1.25B
Net Calls
-$712M
Net Calls Change
-$479M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$114M
2
Citigroup
Citigroup
New York
+$57.5M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$31.4M
4
Two Sigma Investments
Two Sigma Investments
New York
+$26.2M
5
ACI
AMP Capital Investors
Australia
+$25.7M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$169M
2
Goldman Sachs
Goldman Sachs
New York
-$139M
3
N
Natixis
France
-$95.4M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$81.8M
5
JP Morgan Chase
JP Morgan Chase
New York
-$70.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BWP
601
Baldwin Wealth Partners
Massachusetts
$13K – – –
FIB
602
First Interstate Bank
Montana
$13K – – –
DAM
603
Delta Asset Management
Tennessee
$11K – – –
FA
604
Fortis Advisors
Pennsylvania
$11K – – –
AWE
605
Avidian Wealth Enterprises
Texas
$10.7K +$10.7M +99,749 New
BWA
606
Burt Wealth Advisors
Maryland
$9K – – –
JGIA
607
Jackson Grant Investment Advisers
Connecticut
$9K – – –
CAM
608
Close Asset Management
United Kingdom
$8K – – –
CP
609
Corbenic Partners
Pennsylvania
$8K – – –
GTAM
610
Global Trust Asset Management
Florida
$8K +$8.02K +75 New
CIM
611
Contravisory Investment Management
Massachusetts
$8K +$8.34K +78 New
ANBT
612
American National Bank & Trust
Texas
$6K – – –
HCM
613
Highlander Capital Management
New Jersey
$6K – – –
RAM
614
Riggs Asset Management
Pennsylvania
$6K – – –
GI
615
Gradient Investments
Minnesota
$6K +$6.09K +57 New
QAM
616
QCI Asset Management
New York
$5K – – –
MOS
617
MGO One Seven
Ohio
$5K +$4.81K +45 New
PCA
618
Providence Capital Advisors
North Carolina
$4K +$3.53K +33 New
HFM
619
Hartford Financial Management
Connecticut
$3K – – –
FFG
620
Ford Financial Group
California
$3K +$3.42K +32 New
BHB
621
Bank Hapoalim BM
Israel
$2.04K -$141K -1,323 -6%
CCM
622
Cribstone Capital Management
Maine
$2K -$1.6K -15 -50%
Walleye Trading
623
Walleye Trading
New York
$1.52K +$1.25M +11,740 +468%
PCG
624
Private Capital Group
Connecticut
$37 +$36.9K +345 New
QF
625
QVT Financial
New York
– -$41.5M -372,984 Closed
23 24
25
26 27

IBB Hedge Fund Activity: Q4 2017 in Review

624 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2017, worth a combined $5.69B — down 12% from $6.44B a quarter earlier.

Buyers outnumbered sellers: 124 funds opened new IBB positions and 77 closed out — a net gain of 47 holders — while 207 added to existing stakes and 192 trimmed.

The largest buyer was UBS Group, adding an estimated $114M. The largest seller was Morgan Stanley, cutting an estimated $169M.

  • 624 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2017, up from 583 in Q3 2017.
  • Funds reported $5.69B of iShares Biotechnology ETF stock for Q4 2017, down 12% quarter-over-quarter.
  • 124 funds opened new iShares Biotechnology ETF positions in Q4 2017 and 77 closed out, a net change of +47 holders.
  • The largest iShares Biotechnology ETF buyer in Q4 2017 was UBS Group, an estimated $114M added.
  • The largest iShares Biotechnology ETF seller in Q4 2017 was Morgan Stanley, an estimated $169M sold.

Based on aggregated 13F filings for Q4 2017.